bpost: 2Q25 results beat 22%, outlook raised further, room for another upgrade at 3Q25. Lotus Bakeries: APAC factory ahead of schedule. NN Group: 1H on track with May CMD, longevity deal a positive surprise (Sol 2 PF 205%). Talabat: 2Q25 Preview. Vopak: AVTL's FID on Mumbai expansion
42% owned AVTL announced a €170m investment in a greenfield LPG terminal and bottling plant. LPG demand in India has grown at a 7.3% CAGR over the past decade with further attractive growth in demand and terminal imports expected. The Indian JV AVTL was recently listed and the IPO proceeds amounted to ca. €290m to be deployed for debt repayment and further growth initiatives. The listing frees up cash at the Vopak holding which can be deployed for funding other investments or additional sharehol...
AVTL to develop new terminal in JNPA, India AVTL to develop new terminal in JNPA, IndiaRotterdam, the Netherlands, 8 August 2025In India, AVTL announced a positive final investment decision to build a greenfield terminal for 132k cbm LPG and 318k cbm liquid products and a LPG bottling plant of 35,000MT capacity in the JNPA port in Mumbai. This is AVTL's second terminal in the JNPA port which will help grow its market share in servicing a highly industrialized and fast growing hinterland of West and central regions in India. The terminal is expected to be commissioned in phases starting mid ...
CROSSJECT remains engaged during the summer break Press Release CROSSJECT remains engaged during the summer break Maintenance operations are being carried out at production sites.Regulatory and development activities are continuing actively. Dijon, France, August 4, 2025 (5:30 p.m. CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company developing emergency products based on its proprietary ZENEO® needle-free auto-injector technology, remains fully engaged to submitting the ZEPIZURE® dossier for Emergency Use Authorization (EUA). During the s...
CROSSJECT reste mobilisé pendant la coupure estivale Communiqué de Presse CROSSJECT reste mobilisé pendant la coupure estivale Les opérations de maintenance sont déployées sur les sites de production.Les activités réglementaires et de développement se poursuivent activement. Dijon, France 04 août 2025 (17h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), la société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie propriétaire d’auto-injecteurs sans aiguille ZENEO®, reste pleinement mobilisée pour la soumiss...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.